BSE Live
Mar 23, 16:01Prev. Close
384.70
Open Price
381.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 23, 15:57Prev. Close
385.05
Open Price
376.40
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
368.75 (48)
| Cash Flow of SMS Pharmaceuticals (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 93.32 | 66.33 | 5.55 | 68.65 | 91.12 | |
| Net CashFlow From Operating Activities | 81.71 | 50.12 | 22.45 | 40.23 | 90.45 | |
| Net Cash Used In Investing Activities | -123.44 | -52.07 | -29.69 | -27.15 | -151.59 | |
| Net Cash Used From Financing Activities | 47.08 | 30.68 | -31.97 | -6.92 | 92.02 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 5.35 | 28.73 | -39.21 | 6.16 | 30.88 | |
| Cash And Cash Equivalents Begin of Year | 36.04 | 7.31 | 46.58 | 40.42 | 9.54 | |
| Cash And Cash Equivalents End Of Year | 41.39 | 36.04 | 7.38 | 46.58 | 40.42 |
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
09.02.2026
05.01.2026
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
14.11.2025
SMS Pharma Consolidated September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
12.11.2025
SMS Pharma Standalone September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
23.03.2026
Alkem Laboratories gets DCGI nod for Semaglutide Injection; share price fall marginally
23.03.2026
22.03.2026
Sell-on-rise market? SBI Securities sees Nifty under pressure, picks two stocks for the week ahead
20.03.2026
Eris Lifesciences, Natco Pharma to launch generic Ozempic at 90% cheaper price
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth